Genetic test identifies breast cancer patients that can avoid chemotherapy and remain
 

Genomic Health has announced the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

More...